Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure☆
References (31)
- et al.
Coenzyme Q10: a new drug for myocardial ischemia?
Med Clin North Am
(1988) - et al.
Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy
Am J Cardiol
(1990) - et al.
A scale for the estimation of sleep problems in clinical research
J Clin Epidemiol
(1988) Determination of coenzyme Q10, a-tocopherol and cholesterol in biological samples by coupled-column liquid chromatography with coulometric and ultraviolet detection
J Chromotogr
(1988)- et al.
Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris
Am J Cardiol
(1985) - et al.
Isolation of a quinone from beef heart mitochondria
Biochim Biophys Acta
(1957) Survey on the vitamin aspects of coenzyme Q
Int J Vitam Res
(1969)- et al.
Critique of coenzyme Q in biochemical and biomedical research and in ten years of clinical research on cardiovascular disease
Mol Med
(1977) - et al.
Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10
- et al.
Deficiency of coenzyme Q10 in myocardial failure
Drugs Exp Clin Res
(1984)
The function of coenzyme Q in free radical production and as an antioxidant: a review
Chem Scripta
The use of coenzyme Q10 to protect the ischaemic heart muscle
Double blind-double crossover study of coenzyme Q10 in heart failure
Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10
A clinical double blind and cross-over trial with Coenzyme Q10 on patients with cardiac disease
Cited by (152)
CoenzymeQ in cellular redox regulation and clinical heart failure
2021, Free Radical Biology and MedicineCitation Excerpt :There were two small trials (n < 40) that showed no difference in LVEF; those studies included HF patients as young as 18 years or only mildly symptomatic (NYHA II) [158]. When CoQ10 dose and treatment duration were equal (50 mg, 3/day for 3 months), the larger [143] of these 2 studies (n = 79) showed a positive effect for CoQ10 versus baseline (pre-treatment) measurements, while the smaller [167] study (n = 39) [167] showed no difference versus placebo. Despite their different outcomes for LVEF, both of these 3 month studies measured similar increases in plasma CoQ10 concentration (~1.4 mg/L) with a 50 mg CoQ10 dose [143,167].
Nutraceuticals in Patients With Heart Failure: A Systematic Review
2020, Journal of Cardiac FailureCitation Excerpt :Decreased plasma CoQ10 is an independent predictor of mortality in patients with CHF.14 Three systematic reviews,15–17 5 RCTs,18–22 and 1 quasi-experimental study23 were included. Sample sizes ranged from 55 to 641 participants, and follow-up 6 months to 2 years.
Coenzyme q10 in cardiovascular disease: an insight for a potential therapeutic benefit
2023, Natural Resources for Human HealthKorean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure
2023, International Journal of Heart Failure
- ☆
Supported by grants from the Swedish Heart and Lung Foundation and from Pharmacia, Sweden.
- §
See Appendix for a list of members.